Cargando…

Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation

BACKGROUND: In comparison to warfarin, non–vitamin K antagonist oral anticoagulants (NOACs) have the advantages of ease of dosing, fewer drug interactions, and lack of need for ongoing monitoring. We sought to evaluate whether these advantages translate to improved adherence and whether adherence is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yao, Xiaoxi, Abraham, Neena S., Alexander, G. Caleb, Crown, William, Montori, Victor M., Sangaralingham, Lindsey R., Gersh, Bernard J., Shah, Nilay D., Noseworthy, Peter A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4802483/ https://www.ncbi.nlm.nih.gov/pubmed/26908412 http://dx.doi.org/10.1161/JAHA.115.003074

Ejemplares similares

Baseline characteristics and event rates among anticoagulated patients with atrial fibrillation in practice and pivotal NOAC trials
por: Noseworthy, Peter A., et al.
Publicado: (2017)

Patterns of Anticoagulation Use and Cardioembolic Risk After Catheter Ablation for Atrial Fibrillation
por: Noseworthy, Peter A., et al.
Publicado: (2015)

Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation
por: Yao, Xiaoxi, et al.
Publicado: (2016)

Percutaneous Left Atrial Appendage Occlusion in Comparison to Non‐Vitamin K Antagonist Oral Anticoagulant Among Patients With Atrial Fibrillation
por: Noseworthy, Peter A., et al.
Publicado: (2022)

Contemporary trends and barriers to oral anticoagulation therapy in Non-valvular atrial fibrillation during DOAC predominant era
por: Sehrawat, Ojasav, et al.
Publicado: (2023)

Catheter-related complications and mortality of atrial fibrillation ablation following introduction of contact force-sensing technology
por: Akar, Joseph G, et al.
Publicado: (2020)

Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study
por: Abraham, Neena S, et al.
Publicado: (2015)

Comparative Effectiveness of Machine Learning Approaches for Predicting Gastrointestinal Bleeds in Patients Receiving Antithrombotic Treatment
por: Herrin, Jeph, et al.
Publicado: (2021)

Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban
por: Kirchhof, Paulus, et al.
Publicado: (2020)

Anticoagulation for Stroke Prevention in Older Adults with Atrial Fibrillation and Comorbidity: Current Evidence and Treatment Challenges
por: Sabbag, Avi, et al.
Publicado: (2018)

Impact of anemia on major bleeding in patients taking oral anticoagulants for nonvalvular atrial fibrillation
por: Kinjo, Norito, et al.
Publicado: (2023)

Left atrial appendage closure in atrial fibrillation patients with prior major bleeding or ineligible for oral anticoagulation
por: Wintgens, L. I. S., et al.
Publicado: (2019)

Adherence to a Novel Oral Anticoagulant Among Patients with Atrial Fibrillation
por: Zhou, Meijia, et al.
Publicado: (2015)

Assessment of Trends in Statin Therapy for Secondary Prevention of Atherosclerotic Cardiovascular Disease in US Adults From 2007 to 2016
por: Yao, Xiaoxi, et al.
Publicado: (2020)

Challenges of Anticoagulant Therapy in Atrial Fibrillation—Focus on Gastrointestinal Bleeding
por: Scridon, Alina, et al.
Publicado: (2023)

Generalizability of the EAST‐AFNET 4 Trial: Assessing Outcomes of Early Rhythm‐Control Therapy in Patients With Atrial Fibrillation
por: Dickow, Jannis, et al.
Publicado: (2022)

Is Atrial Fibrillation Management as Simple as ABC?
por: Yao, Xiaoxi, et al.
Publicado: (2020)

Burden of major gastrointestinal bleeding among oral anticoagulant-treated non-valvular atrial fibrillation patients
por: Deitelzweig, Steven, et al.
Publicado: (2021)

Predicting major bleeding among hospitalized patients using oral anticoagulants for atrial fibrillation after discharge
por: Qazi, Jakub Z., et al.
Publicado: (2021)

Comparing risk of major bleeding between users of different oral anticoagulants in patients with nonvalvular atrial fibrillation
por: Souverein, Patrick C., et al.
Publicado: (2020)

Prognostic significance of patent foramen ovale in anticoagulated patients with atrial fibrillation
por: Melduni, Rowlens M, et al.
Publicado: (2020)

Cost Conversations About Anticoagulation Between Patients With Atrial Fibrillation and Their Clinicians: A Secondary Analysis of a Randomized Clinical Trial
por: Kamath, Celia C., et al.
Publicado: (2021)

Cognitive function and adherence to anticoagulation treatment in patients with atrial fibrillation
por: Jankowska-Polańska, Beata, et al.
Publicado: (2016)

Adherence to oral anticoagulation in ischemic stroke patients with atrial fibrillation
por: Tiili, Paula, et al.
Publicado: (2021)

Anticoagulant Treatment Adherence and Persistence in German Patients with Atrial Fibrillation
por: Patti, Giuseppe, et al.
Publicado: (2023)

New Cancer Diagnosis After Bleeding in Anticoagulated Patients With Atrial Fibrillation
por: Raposeiras Roubín, Sergio, et al.
Publicado: (2020)

A new model to predict major bleeding in patients with atrial fibrillation using warfarin or direct oral anticoagulants
por: Claxton, J’Neka S., et al.
Publicado: (2018)

Major Bleeding Risk in Patients With Non-valvular Atrial Fibrillation Concurrently Taking Direct Oral Anticoagulants and Antidepressants
por: Chang, Kuo-Hsuan, et al.
Publicado: (2022)

Major Bleeding Risk in Atrial Fibrillation Patients Co-Medicated With Non-Vitamin K Oral Anticoagulants and Antipsychotics
por: Chen, Chiung-Mei, et al.
Publicado: (2022)

Therapeutic Strategies Following Major, Clinically Relevant Nonmajor, and Nuisance Bleeding in Atrial Fibrillation: Findings From ORBIT‐AF
por: O'Brien, Emily C., et al.
Publicado: (2018)

Impact of Primary Hemostasis Disorders on Late Major Bleeding Events among Anticoagulated Atrial Fibrillation Patients Treated by TAVR
por: Dietrich, Laurent, et al.
Publicado: (2021)

Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients With High Risk of Gastrointestinal Bleeding
por: Lip, Gregory Y. H., et al.
Publicado: (2021)

Bleeding complications in patients with gastrointestinal cancer and atrial fibrillation treated with oral anticoagulants
por: Ording, Anne Gulbech, et al.
Publicado: (2021)

Concomitant Use of Diltiazem With Direct Oral Anticoagulants and Bleeding Risk in Atrial Fibrillation
por: Xu, Yunwen, et al.
Publicado: (2022)

Correction to: Anticoagulant Treatment Adherence and Persistence in German Patients with Atrial Fibrillation
por: Patti, Giuseppe, et al.
Publicado: (2023)

Anticoagulation in atrial fibrillation
por: Steinberg, Benjamin A, et al.
Publicado: (2014)

Anticoagulation in atrial fibrillation: the present and the future
por: Dweck, Marc R, et al.
Publicado: (2012)

The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation
por: O'Brien, Emily C., et al.
Publicado: (2015)

Effect of Shared Decision‐Making for Stroke Prevention on Treatment Adherence and Safety Outcomes in Patients With Atrial Fibrillation: A Randomized Clinical Trial
por: Noseworthy, Peter A., et al.
Publicado: (2022)

Major Bleeding Complications and Persistence With Oral Anticoagulation in Non‐Valvular Atrial Fibrillation: Contemporary Findings in Real‐Life Danish Patients
por: Lamberts, Morten, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_4gce19e6d09t7c0p29co53r7dm